J Liver Cancer Search

CLOSE


J Liver Cancer > Volume 16(1); 2016 > Article
Journal of Liver Cancer 2016;16(1):7-11.
DOI: https://doi.org/10.17998/jlc.16.1.7    Published online March 31, 2016.
Evaluation of the Outcome after Transarterial Chemoembolization; Refinement of Barcelona Clinic Liver Cancer Stage-B from Eastern Point of View
Namiki Izumi
Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
Copyright ©2016 by The Korean Liver Cancer Association
Abstract
Transarterial chemoembolization (TACE) is recommended as the first line treatment option for the patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC), however, treatment strategy and evaluation of effects after TACE has not been fully established. Recently, sub-stage of BCLC stage B has been proposed and validated, but it should be validated including a large number of the patients and its refinement should be discussed. We have validated the sub-stage of BCLC stage B (B1-B4) by comparing overall survival after TACE, and there was no statistically significant difference in overall survival after TACE between B1 and B2. After excluding the patients with Child-Pugh point 7 from B1, the overall survival was significantly better than that of B2. Therefore, up-to-seven criteria is shown to be a reliable tool for the treatment strategy in the patients with intermediate stage of HCC. Refinement of sub-stage of BCLC stage B has been proposed by some other institutes, and it is important to establish novel treatment strategy for the patients with BCLC stage B after TACE to improve the prognosis of the patients after TACE, and to define the best timing for conversion to sorafenib or liver transplantation should be discussed. (J Liver Cancer 2016;16:7-11)
Key Words: Hepatocellular carcinoma; Barcelona Clinic Liver Cancer stage; Subclassification; Chemoembolization
NULL


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
1527 Gangnam Finance Plaza (FASTFIVE), 419 Teheran-ro, Gangnam-gu, Seoul 06160, Korea
Tel: +82-2-313-1900    E-mail: liver@klcsg.or.kr                

Copyright © 2019 by The Korean Liver Cancer Association. All rights reserved.

Developed in M2community

Close layer
prev next